Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 1/20 | 0.48 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | DPP4 | P27487 | 2/20 | 0.48 |
| ▸ | F2 | P00734 | 1/20 | 0.48 |
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1168889 | 1.00 | ADRA2A (0.48) | ADRA2AADRA2CLMNAHIF1AKDM4E | |
| SCHEMBL17504544 | 0.85 | ADRA2A (0.54) | ADRA2AADRA2CLMNAHIF1AKDM4E | |
| SCHEMBL6745618 | 0.84 | DPP4 (0.58) | ADRA2AADRA2CLMNAHIF1AKDM4E | |
| SCHEMBL20634768 | 0.80 | DPP4 (0.62) | ADRA2AADRA2CLMNAHIF1AKDM4E | |
| SCHEMBL5872238 | 0.79 | ADRA2A (0.58) | ADRA2AADRA2CLMNAHIF1AKDM4E | |
| SCHEMBL1168170 | 0.79 | ADRA2A (0.58) | ADRA2AADRA2CLMNAHIF1AKDM4E | |
| SCHEMBL15667190 | 0.79 | ADRA2A (0.58) | ADRA2AADRA2CLMNAHIF1AKDM4E | |
| SCHEMBL15586 | 0.78 | TAAR1 (0.48) | ADRA2AADRA2CLMNAHIF1AKDM4E | |
| SCHEMBL5872340 | 0.78 | TAAR1 (0.43) | ADRA2AADRA2CLMNAHIF1AKDM4E | |
| SCHEMBL22703495 | 0.76 | ADRA2C (0.68) | ADRA2AADRA2CLMNAHIF1AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3768659-B1 | AN IMPROVED ASYMMETRIC SYNTHESIS OF ALPHA-(DIARYLMETHYL) ALKYL AMINES | PIRAMAL PHARMA LTD (IN) | 2023-07-19 | — | — | EP | disclosed |
| US-11279668-B2 | Asymmetric synthesis of alpha-(diarylmethyl) alkyl amines | PIRAMAL PHARMA LIMITED (IN) | 2022-03-22 | — | — | US | disclosed |
| US-20210061752-A1 | AN IMPROVED ASYMMETRIC SYNTHESIS OF alpha-(DIARYLMETHYL) ALKYL AMINES | Piramal Enterprises Limited (IN) | 2021-03-04 | — | — | US | disclosed |
| US-7126028-B1 | Process for preparing chiral compounds | THE UNIVERSITY COURT OF THE UNIVERSITY OF ST. ANDREWS (GB) | 2006-10-24 | — | — | US | disclosed |
| EP-1135349-A1 | PROCESS FOR PREPARING CHIRAL COMPOUNDS | UNIVERSITY OF DURHAM (GB) | 2001-09-26 | — | — | EP | disclosed |
| WO-2000034210-A1 | PROCESS FOR PREPARING CHIRAL COMPOUNDS | UNIVERSITY OF DURHAM (GB) | 2000-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210061752-A1 | AN IMPROVED ASYMMETRIC SYNTHESIS OF alpha-(DIARYLMETHYL) ALKYL AMINES | SAT1, BET1, SRM | ADRA2A 451/4885ADRA2C 614/4885LMNA 1464/4885 |
| US-11279668-B2 | Asymmetric synthesis of alpha-(diarylmethyl) alkyl amines | SAT1, SRM, SMS | ADRA2A 348/4885ADRA2C 458/4885LMNA 1647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.